These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 4020632)

  • 1. Synthesis and pharmacological evaluation of aromatic dihydroxylated spiro[indan-1,3'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives.
    Sommerville R; Rosenberg HE; Crooks PA
    J Pharm Sci; 1985 May; 74(5):553-5. PubMed ID: 4020632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthesis and analgesic activities of some spiro[indan-1,3'-pyrrolidine] derivatives designed as rigid analogs of profadol.
    Crooks PA; Sommerville R
    J Pharm Sci; 1982 Mar; 71(3):291-4. PubMed ID: 6461753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
    Crooks PA; Rosenberg HE
    J Med Chem; 1978 Jun; 21(6):585-7. PubMed ID: 671457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synthesis and antinociceptive properties of spiro (indan -2, 2(1) -pyrrolidine), spiro (tetralin -2, 2(1) - pyrrolidine) and their N-methyl derivatives [proceedings].
    Crooks PA; Rosenberg HE
    J Pharm Pharmacol; 1976 Dec; 28 Suppl():83P. PubMed ID: 12363
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide.
    Crider AM; Hemdi TF; Hassan MN; Fahn S
    J Pharm Sci; 1984 Nov; 73(11):1585-7. PubMed ID: 6549185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation by ascorbic acid of dopamine agonist and antagonist binding sites in striatum.
    Kayaalp SO; Neff NH
    Life Sci; 1980 Jun; 26(22):1837-41. PubMed ID: 7401904
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
    Weinstock J; Gaitanopoulos DE; Oh HJ; Pfeiffer FR; Karash CB; Venslavsky JW; Sarau HM; Flaim KE; Hieble JP; Kaiser C
    J Med Chem; 1986 Sep; 29(9):1615-27. PubMed ID: 2875183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and D2 dopaminergic activity of pyrrolidinium, tetrahydrothiophenium, and tetrahydrothiophene analogues of sulpiride.
    Harrold MW; Wallace RA; Farooqui T; Wallace LJ; Uretsky N; Miller DD
    J Med Chem; 1989 Apr; 32(4):874-80. PubMed ID: 2522993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.
    Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Horn AS
    Eur J Pharmacol; 1985 Feb; 109(2):229-40. PubMed ID: 3922776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible anomalous behaviour of apomorphine in relation to other dopamine receptor agonists.
    Feenstra MG; Goedemoed JH; Rollema H; Horn AS
    J Pharm Pharmacol; 1983 Jul; 35(7):471-3. PubMed ID: 6136595
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
    Gao YG; Ram VJ; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1990 Jan; 33(1):39-44. PubMed ID: 2136919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites.
    Leff S; Adams L; Hyttel J; Creese I
    Eur J Pharmacol; 1981 Mar; 70(1):71-5. PubMed ID: 7215442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of kainic acid on striatal dopamine receptors.
    Weinreich P; Seeman P
    Brain Res; 1980 Oct; 198(2):491-6. PubMed ID: 7407614
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of some 6-substituted 7-methyl-1,4-dioxa-7-azaspiro[4.5]decanes as potential dopamine agonists.
    Brubaker AN; Colley M
    J Med Chem; 1986 Aug; 29(8):1528-31. PubMed ID: 3735319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stereochemical explanation of the dopamine agonist and antagonist activity of stereoisomeric pairs.
    Froimowitz M; Neumeyer JL; Baldessarini RJ
    J Med Chem; 1986 Sep; 29(9):1570-3. PubMed ID: 3746808
    [No Abstract]   [Full Text] [Related]  

  • 16. Binding of [3H]apomorphine to striatal membranes prepared from rat brain after 6-hydroxydopamine and kainic acid lesions.
    Fujita N; Saito K; Iwatsubo K; Hirata A; Noguchi Y; Yoshida H
    Brain Res; 1980 May; 190(2):593-6. PubMed ID: 7370810
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine receptor binding regulated by guanine nucleotides.
    Creese I; Usdin TB; Snyder SH
    Mol Pharmacol; 1979 Jul; 16(1):69-76. PubMed ID: 481426
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and dopamine agonist and antagonist effects of (R)-(-)- and (S)-(+)-11-hydroxy-N-n-propylnoraporphine.
    Gao Y; Zong R; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1988 Jul; 31(7):1392-6. PubMed ID: 3385732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding.
    Sibley DR; Weinberger S; Segal DS; Creese I
    Experientia; 1982 Oct; 38(10):1224-5. PubMed ID: 6890464
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and analgesic properties of some conformationally restricted analogues of profadol.
    Crooks PA; Szyndler R
    J Med Chem; 1980 Jun; 23(6):679-82. PubMed ID: 6446605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.